These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1906746)

  • 1. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3.
    Kemnitz J; Cremer J; Schaefers HJ; Restrepo-Specht I; Haverich A; Uysal A; Heublein B; Wirth S
    J Heart Lung Transplant; 1991; 10(3):366-72. PubMed ID: 1906746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive implications of bioptic diagnosis in cardiac allografts.
    Kemnitz J; Choritz H; Cohnert TR; Haverich A; Borst HG; Georgii A
    J Heart Transplant; 1989; 8(4):315-29. PubMed ID: 2671317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
    Kormos RL; Herlan DB; Armitage JM; Stein K; Kaufman C; Zeevi A; Duquesnoy R; Hardesty RL; Griffith BP
    J Heart Transplant; 1990; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.
    Tsamandas AC; Pham SM; Seaberg EC; Pappo O; Kormos RL; Kawai A; Griffith BP; Zeevi A; Duquesnoy R; Fung JJ; Starzl TE; Demetris AJ
    J Heart Lung Transplant; 1997 Jul; 16(7):723-34. PubMed ID: 9257254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
    Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
    J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OKT3 treatment of cardiac allograft rejection.
    Haverty TP; Sanders M; Sheahan M
    J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB; Renlund DG; Hammond EH; Wittwer CT; Yowell RL; DeWitt CW; Jones KW; Gay WA; Menlove RL; Bristow MR
    J Heart Lung Transplant; 1991; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies of endomyocardial biopsies from heart transplant recipients on RATG and OKT3 immunoprophylaxis protocols.
    Kaufman C; Zeevi A; Zerbe T; Kormos R; Griffith B; Hardesty R; Duquesnoy RJ
    Transplantation; 1989 Oct; 48(4):621-5. PubMed ID: 2799915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
    J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic OKT3 used as induction therapy for heart transplantation.
    Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE
    Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Atkinson JB; Stewart JR; Hammon JW; Bender JW
    J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Quilty effect" in heart transplantation: is it related to acute rejection?
    Pardo-Mindán FJ; Lozano MD
    J Heart Lung Transplant; 1991; 10(6):937-41. PubMed ID: 1756159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
    Wagner FM; Reichenspurner H; Uberfuhr P; Kur F; Kaulbach HG; Meiser BM; Ziegler U; Reichart B
    J Heart Lung Transplant; 1994; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization.
    Moore CK; O'Connell JB; Renlund DG; Bristow MR; Hammond EH
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1055-8. PubMed ID: 1899151
    [No Abstract]   [Full Text] [Related]  

  • 19. Some histopathologic aspects regarding onset of antirejection therapy after heart transplantation.
    Kemnitz J; Heublein B; Haverich A; Cohnert TR; Hetzer R; Zerkowski HR; Altmannsberger M; Georgii A
    J Heart Transplant; 1990; 9(6):662-7. PubMed ID: 2277305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.